- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06284330
CHARGE Study: CHoice ARchitecture Genetic tEsting (CHARGE)
April 3, 2024 updated by: Sukh Makhnoon, University of Texas Southwestern Medical Center
CHARGE: CHOICE ARCHITECTURE IN GENETIC TESTING
CHARGE is a hybrid type I feasibility study to compare a choice architecture intervention for cascade genetic testing to usual care.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
CHARGE study contains two arms: Arm 1) Usual care, comprising of standard genetic counseling and education to probands regarding cascade testing; and Arm 2) Direct mailing of a home genetic testing kit to probands' at-risk relatives that can be returned directly to a commercial genetic testing laboratory, including educational information on the importance and cost of cascade testing
Study Type
Interventional
Enrollment (Estimated)
260
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sukh Makhnoon, PhD, MS
- Phone Number: 214-638-3242
- Email: Chargestudy@utsouthwestern.edu
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390
- Recruiting
- UT Southwestern Medical Center
-
Principal Investigator:
- Sukh Makhnoon, PhD, MS
-
Contact:
- Sukh Makhnoon, PhD, MS
- Phone Number: 214-648-3242
- Email: Chargestudy@utsouthwestern.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Proband Inclusion Criteria:
- Have a newly reported pathogenic or likely pathogenic variant in one or more of the following genes: APC, ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, MLH1, MSH2, MSH6, PMS2, PTEN, TP53
- 18 years of age or older
- English fluency
- Have at least 1 adult living genetically related relative who resides in Texas
Proband Exclusion Criteria:
- Referred for genetic testing by a relative with a pathogenic variant
- Unwilling to be randomized to a study arm
Relative Inclusion Criteria:
- 18 years of age or older
- English fluency
- Residing in Texas
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard of care cascade testing
Standard of care cascade genetic testing
|
|
Experimental: Choice architecture cascade testing
Direct mailed genetic testing kit to probands' relatives.
|
Direct mailed at-home genetic testing kit to probands' relatives.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of cascade genetic testing
Time Frame: 3-6 months
|
Proportion of at-risk relatives who undergo testing
|
3-6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in probands' family communication about genetic test results as measured by Proband survey
Time Frame: Baseline and 4-7 months
|
Frequency and content of family communication will be measured by Proband survey (result sharing, reasons for sharing and not sharing)
|
Baseline and 4-7 months
|
Proband's and relative's satisfaction with decision about participating in study measured at approximately 4- 7 months
Time Frame: Approx. 4-7 months
|
Probands' and relative's satisfaction with decision about participating in study will be measured at approximately 4- 7 months using surveys (intervention arm).
This is measured using the satisfaction with decision scale.
|
Approx. 4-7 months
|
Family functioning as reported by probands and relatives measured by Cancer Family Impact Scale
Time Frame: 4-7 months
|
Relatives' and probands' family functioning will be measured by a survey that includes the adapted Cancer Family Impact Scale.
Participants responses to the 18 items of CFIS on a 5-point Likert scale are summed for scoring.
Higher summed scores indicated a greater communication and flow of about cancer information within family and therefore better family functioning.
|
4-7 months
|
Proband's reaction to intervention materials as measured by proband survey.
Time Frame: 4-7 months
|
Proband survey will include adapted versions of usability questions, commonly used in usability tests of eHealth tools that assess satisfaction, liking, ease of use, and preference.
Possible scores range from 0-5 where lower score indicates better outcome.
|
4-7 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sukh Makhnoon, PhD, MS, UT Southwestern Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 16, 2024
Primary Completion (Estimated)
March 1, 2025
Study Completion (Estimated)
August 1, 2025
Study Registration Dates
First Submitted
February 1, 2024
First Submitted That Met QC Criteria
February 27, 2024
First Posted (Actual)
February 28, 2024
Study Record Updates
Last Update Posted (Actual)
April 5, 2024
Last Update Submitted That Met QC Criteria
April 3, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- STU-2023-0881
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Cancer
-
M.D. Anderson Cancer CenterRecruiting
-
Myriad Genetic Laboratories, Inc.Myriad Genetics, Inc.CompletedHereditary CancerUnited States
-
University of PennsylvaniaFox Chase Cancer CenterCompletedCardiovascular Diseases | Cancer | Hereditary Cancer | Hereditary Cardiac AmyloidosisUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Georgetown UniversityNot yet recruitingHereditary Cancer | Genetic Testing
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedHereditary Cancer | Genetic CounselingMexico
-
Pro-Change Behavior SystemsRecruitingMental Health Issue | Hereditary CancerUnited States
-
InheRET, IncUniversity of MichiganEnrolling by invitationHereditary Cancer-Predisposing SyndromeUnited States
-
Weill Medical College of Cornell UniversityRecruitingGynecologic Cancer | Hereditary Cancer SyndromeUnited States
-
Myriad Genetic Laboratories, Inc.Completed
-
Institut Claudius RegaudUnknownHereditary Breast and Ovarian Cancer | Hereditary Cancer Syndrome | Hereditary Colorectal Endometrial Cancer SyndromeFrance
Clinical Trials on Enhanced cascade testing
-
Washington University School of MedicineThe Foundation for Barnes-Jewish HospitalTerminatedLynch Syndrome | Hereditary Breast and Ovarian CancerUnited States
-
Claremont Graduate UniversityAHMC Health FoundationCompletedType 2 DiabetesUnited States
-
University of VirginiaRecruitingUrologic Diseases | Myelomeningocele | Neurogenic Bladder | Tethered Cord Syndrome | Bladder, Neurogenic | Neurologic DysfunctionUnited States
-
WaveForm Technologies Inc.UnknownContinuous Glucose Monitoring
-
University of Puget SoundCompleted
-
WaveForm Technologies Inc.CompletedEfficacy of a 21-Day Wear Period for the Cascade CGMCroatia, Slovenia
-
Canterbury Christ Church UniversityInterreg 2 Seas Mers ZeeenWithdrawn
-
Isfahan University of Medical SciencesUnknownFamilial HypercholesterolemiaIran, Islamic Republic of
-
University of BaselRecruitingLynch Syndrome | Hereditary Breast and Ovarian CancerSwitzerland
-
Northwestern UniversityUniversity of Pennsylvania; Family Heart FoundationEnrolling by invitationFamilial HypercholesterolemiaUnited States